Screener
BioMarin Pharmaceuticals BMRN Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| ASSETS | June 30, 2026 / (unaudited) | December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Property, plant and equipment, net | 989,994 | 952,508 |
| Intangible assets, net | 4,879,367 | 213,837 |
| Goodwill | 655,745 | 196,199 |
| Deferred tax assets | 888,575 | 1,508,697 |
| Other assets | 338,138 | 277,049 |
| Total assets | $11,723,442 | $7,594,022 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's deferred tax assets?
- BioMarin Pharmaceuticals (BMRN) reported deferred tax assets of $888.58M in Q2 2026.
- How has BioMarin Pharmaceuticals's deferred tax assets changed year-over-year?
- BioMarin Pharmaceuticals's deferred tax assets decreased by 37.7% year-over-year, from $1.43B to $888.58M.
- What is the long-term trend for BioMarin Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's deferred tax assets has grown at a 1.0% compound annual growth rate (CAGR), from $1.43B to $1.51B.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about BioMarin Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude